Top news of the week: 14.12.2022.
Amgen in Advanced Talks to Buy Horizon Therapeutics
The U.S. biotech company was the last of three suitors standing in an auction for the drugmaker. A deal would likely be valued at well over $20 billion and mark the largest healthcare ...
Beyond Biotech podcast 25: Center for Global Development, Humacyte, Transgene
This week, we have three guests, from Transgene, Humacyte and the Center for Global Development, as well as with JLL.
Ginkgo Bioworks launches Ginkgo Enzyme Services
Ginkgo Bioworks has announced the launch of Ginkgo Enzyme Services to help solve challenges for R&D teams developing enzymes.
Nordic Nanovector In Limbo As Merger Collapses
<p>The board has resigned at the crisis-hit Norwegian firm after shareholders voted against a reverse merger with APIM Therapeutics.</p> <br class="t-last-br" />
Flagship-Backed Biotech Uses Naturally-Occurring Molecules to Treat Chronic Disease
Flagship Pioneering has committed $50 million to Montai Health, a biotech that aims to develop therapies for chronic diseases using molecules already found in nature.
Biopharma deal activity slipping, M&As remain low
While biopharma deal values were down year-over-year in November by 7.6%, that gap has now doubled, showing a 15.5% decline in values in 2022. There has been a significant slowdown in ...
The Dish’s Biotechnology News Wrap Up – December 9, 2022
*|RSSFEED:DATE|* Incase you missed it. We summarized the week's top biotechnology stories.
Amgen agrees $26bn for Horizon following Sanofi withdrawal
Bloomberg has reported that Amgen has agreed to purchase Horizon for €24.7 billion ($26bn), in a deal which could yet see further delays